US equities |
SPCX $167.15 ▲+5.15% NVDA $237.12 ▲+1.36% MU $1,063.89 ▼-1.02% TSLA $377.81 ▲+1.95% MSFT $526.93 ▲+1.82% SNDK $1,714.52 ▼-0.32% INTC $116.64 ▼-2.26% META $746.00 ▲+2.46%
FinancialContent

Sarepta Therapeutics, Inc. - Common Stock (NQ:SRPT)

17.26 -0.24 (-1.37%)
Delayed Quote Updated: 11:22 AM EDT, Oct 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sarepta Therapeutics, Inc. - Common Stock

< Previous 1 2
...
16 17 18 19 20 21 22 23 24
...
36 37 Next >
News headline image
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Sarepta Therapeutics, Inc.
Via Business Wire
News headline image
Arrowhead Pharmaceuticals Shares Are On The Rise Today: What's Going On? ↗
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) shares are trading higher Tuesday after the company announced a global licensing and collaboration agreement with Sarepta Therapeutics Inc. (NASDAQ: SRPT).... 
Via Benzinga
News headline image
J.M. Smucker Posts Upbeat Earnings, Joins LexinFintech, Semtech, Arrowhead Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday ↗
 
Via Benzinga
News headline image
Arrowhead Launches 25% On A Massive Licensing Deal With Sarepta ↗
The deal focuses on four clinical-stage drugs, three preclinical assets and a potential five new targets. 
Via Investor's Business Daily
News headline image
Analyst Expectations For Sarepta Therapeutics's Future ↗
 
Via Benzinga
News headline image
Peeling Back The Layers: Exploring Sarepta Therapeutics Through Analyst Insights ↗
 
Via Benzinga
News headline image
Unveiling 15 Analyst Insights On Sarepta Therapeutics ↗
 
Via Benzinga
News headline image
Sarepta Therapeutics Announces Global Licensing and Collaboration Agreement with Arrowhead Pharmaceuticals for Multiple Clinical and Preclinical siRNA Programs
From Sarepta Therapeutics, Inc.
Via Business Wire
News headline image
This Sarepta Therapeutics Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Monday ↗
 
Via Benzinga
News headline image
Sarepta Therapeutics To Rally Around 30%? Here Are 10 Top Analyst Forecasts For Thursday ↗
 
Via Benzinga
News headline image
This McKesson Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday ↗
 
Via Benzinga
News headline image
Analyst Scoreboard: 12 Ratings For Sarepta Therapeutics ↗
 
Via Benzinga
News headline image
Unveiling 26 Analyst Insights On Sarepta Therapeutics ↗
 
Via Benzinga
News headline image
Sarepta Therapeutics (SRPT) Q3 2024 Earnings Call Transcript ↗
SRPT earnings call for the period ending September 30, 2024. 
Via The Motley Fool
Topics Earnings
News headline image
Sarepta Therapeutics Announces Third Quarter 2024 Financial Results and Recent Corporate Developments
From Sarepta Therapeutics, Inc.
Via Business Wire
News headline image
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Sarepta Therapeutics, Inc.
Via Business Wire
News headline image
Sarepta Therapeutics to Announce Third Quarter 2024 Financial Results
From Sarepta Therapeutics, Inc.
Via Business Wire
News headline image
This GE Vernova Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday ↗
 
Via Benzinga
News headline image
After US Senator, Unions Urge Federal Trade Commission To Block Novo's $16.5B Acquisition Of Catalent ↗
Public interest groups are urging the FTC to block Novo Holdings' $16.5 billion acquisition of Catalent, citing concerns over reduced competition in critical areas like diabetes, obesity treatments,... 
Via Benzinga
News headline image
Avidity Biosciences, Up 441%, Nears Another Record High As Dystrophy Space Heats Up ↗
The company is working on treatments for forms of muscular dystrophy, and is taking on some of the biggest names in pharma. 
Via Investor's Business Daily
News headline image
2 High-Flying Growth Stocks With Massive Upside Potential ↗
These innovative drugmakers have potential catalysts ahead. 
Via The Motley Fool
News headline image
Better Biotech Stock: Wave Life Sciences vs. Sarepta Therapeutics ↗
These two could become direct competitors relatively soon. 
Via The Motley Fool
News headline image
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Sarepta Therapeutics, Inc.
Via Business Wire
News headline image
Capricor Therapeutics Is Up Over 100%, Could Rise Even Higher
Capricor Therapeutics Inc. (NASDAQ: CAPR) is a biotechnology firm focused on developing cell and exosome-based treatments for rare diseases like iomyopathy 
Via MarketBeat
News headline image
Sarepta Therapeutics to Present New Data from its Neuromuscular Portfolio at 2024 World Muscle Society Congress
From Sarepta Therapeutics, Inc.
Via Business Wire
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
Sarepta Therapeutics Appoints Deirdre Connelly to its Board of Directors
From Sarepta Therapeutics, Inc.
Via Business Wire
News headline image
These 2 Biotech Stocks Are Set to Soar ↗
Innovative drugmakers developing treatments for conditions with high unmet needs can produce lucrative wins. 
Via The Motley Fool
News headline image
Sarepta Therapeutics Announces Recipients of the 7th Annual Route 79, The Duchenne Scholarship Program, for the 2024-2025 Academic Year
From Sarepta Therapeutics, Inc.
Via Business Wire
News headline image
Muscle Disease Drug Developer Dyne Therapeutics Stock Plunges After Updated Data From Duchenne Muscular Dystrophy ↗
Dyne Therapeutics revealed new clinical data from its Phase 1/2 DELIVER trial of DYNE-251 for Duchenne muscular dystrophy, showing significant increases in dystrophin expression and meaningful... 
Via Benzinga
< Previous 1 2
...
16 17 18 19 20 21 22 23 24
...
36 37 Next >